Handbook of Clinical medicine

be of some help to families. 13 Sodium valproate is associated with signifi cantly risk of birth and developmental defects in children born to exposed mothers. Use in women of childbearing potential with caution and only after counselling. __OOHHCCMM__1100ee..iinnddbb 449922 0022//0055//22001177 1199::0088 ygolorueN Anti-epileptic drugs (AEDS): typical adult doses and side-eff ects 493 Carbamazepine: (As slow-release.) Initially 100mg/12h, increase by 200mg/d eve- ry 2wks up to max 1000mg/12h. SE: leucopenia, diplopia, blurred vision, impaired balance, drowsin ess, mild generalized erythematous rash, SIADH (rare; see p673). Lamotrigine: As monotherapy, initially 25mg/d,  by 50mg/d every 2wks up to 100mg/12h (max 250mg/12h). Halve monotherapy dose if on valproate; double if on carbamazepine or pheny toin (max 350mg/12h). SE: maculopapular rash—occurs in 10% (but 1/1000 develop Stevens-Johnson syndrome or toxic epidermal necroly- sis) typically in 1st 8wks, especially if on valproate; warn patients to see a doctor at once if rash or fl u symptoms develop; Other SES: diplopia, blurred vision, photosen- sitivity, tremor, agita tion, vomiting, aplastic anaemia. Levetiracetam: Initially 250mg/24h, increase by 250mg/12h every 2wks up to max 1 . 5g/12h (if eGFR >80). SE: psychiatric side-eff ects are common, eg depression, agi- tation. Other SES: D&V, dyspepsia, drowsiness, diplopia, blood
